Recipients of the Award
2011
The Collaboration for Health in PNG (CHPNG): The Collaboration for Health in PNG is a consortium of pharmaceutical companies working with NGOs to combat the rise of HIV/AIDS in Papua New Guinea. Through the CHPNG, more than 50,000 people in Papua New Guinea have accessed professional counseling and 3000 are currently receiving HIV care. The Collaboration has provided workshops for 250 doctors, nurses, health administrators, counselors and lab technicians. The work of the CHPNG has made a material difference to the lives of people living with HIV/AIDS in PNG. The consortium includes Gilead, Boeringer-Ingelheim, MSD, ViiV, Janssen and Pfizer.
2010
Ms Dell Kingsford-Smith (Janssen) played an integral role in shaping and implementing significant improvements regarding access to medicines and business certainty for the industry, through her leadership on both the Access Strategic Committee and the Health Economics Working Group. In particular, Dell helped to drive a number of transparency initiatives including the publication of the PBAC agenda, PBAC outcomes and PBAC public summary documents. She was also instrumental in the evolution of the PBAC Guidelines. Amongst other things, a review of the Guidelines was required to take into account the advances in Health Technology Assessment theory.
2009
Will Delaat (Independent Chairman Medicines Australia) for significant contributions to the Australian pharmaceutical industry for over 35 years, including twelve years on the Medicines Australia board serving as Chair, Vice Chair and Board member. He has been instrumental in significant policy changes or initiatives and significant relationship building activities to extend the industry’s circle of influence and collaborative and constructive approaches in working with Government.
2008
Mitch Kirkman (Novartis Pharmaceuticals Australia) for outstanding leadership and commitment to the pharmaceutical industry in Australia, including exceptional achievement as Chair of the Research and Development Taskforce from 2004 to 2008, securing a much improved the regulatory environment for clinical trials in Australia.
2007
Michelle Burke (Bristol-Myers Squibb) for her outstanding leadership of the PBS Reform Implementation Group.
2006
Mr David Grainger (Eli Lilly) for outstanding leadership and commitment to the development of the pharmaceuticals industry in Australia, including his exceptional contribution as Chair of Medicines Australia’s PBS Reform Taskforce.
2005
Dr Graeme Blackman (IDT Australia) for his role in steering the Pharmaceutical Industry Action Agenda since its conception in 2000.
2004
Post-PBAC Review Committee. The Post-PBAC Review committee excelled in the negotiations undertaken with the Department of Health & Ageing in securing recommendations to post-PBAC process that will assist the industry in more timely and transparent market access. The committee actively led industry’s involvement in the review from mid-2003 until it’s conclusion. The committee members were: Mr Jeays Lilley, AstraZeneca; Mr Steve Crowley, Janssen-Cilag; and Ms Michelle Burke, Bristol Myers Squibb.
2003
2002
Pharmaceutical Industry Action Agenda Team. The team included Sara Pantzer from Merck Sharp and Dohme, Michelle Burke and Jenny Johnston from Bristol-Myers Squibb, Justin Ooi from AstraZeneca and Paulette Quang from Medicines Australia.The team devoted long hours and their knowledge from mid 2001 through to August 2002 to tie the strings together from an industry plan which emerged from the early work of the Leaders Group and Forums which were held during the process.
Page updated: April 2012